Cardiovascular Innovations and Applications最新文献_第8页

Berberine Ameliorates Diabetic Cardiomyopathy in Mice by Decreasing Cardiomyocyte Apoptosis and Oxidative Stress 小檗碱通过降低心肌细胞凋亡和氧化应激改善小鼠糖尿病性心肌病

4区医学

Cardiovascular Innovations and Applications Pub Date : 2023-01-01 DOI: 10.15212/cvia.2023.0064

Xiaoqiang Sun, Zhuqing Li, Li Wang, Yanxin Wang, Chengzhi Lu

{"title":"Berberine Ameliorates Diabetic Cardiomyopathy in Mice by Decreasing Cardiomyocyte Apoptosis and Oxidative Stress","authors":"Xiaoqiang Sun, Zhuqing Li, Li Wang, Yanxin Wang, Chengzhi Lu","doi":"10.15212/cvia.2023.0064","DOIUrl":"https://doi.org/10.15212/cvia.2023.0064","url":null,"abstract":"Background: Diabetic cardiomyopathy is a multifaceted complication of diabetes that lacks effective treatments. Berberine (BBR), a bioactive compound from Rhizoma coptidis , has potential therapeutic implications, but its precise role in diabetic cardiomyopathy remains to be defined. Methods: In this study, a diabetic cardiomyopathy model was established by administration of a high-fat diet and streptozotocin injection to C57BL/6J mice. Concurrently, the mice received BBR treatment daily for a duration of 8 weeks. After the treatment period, myocardial injury, cardiac function, and the levels of oxidative stress and apoptosis were assessed. Results: BBR significantly ameliorated cardiac dysfunction and histopathological damage caused by diabetic cardiomyopathy. This treatment also elevated serum superoxide dismutase levels while decreasing malondialdehyde levels. The anti-apoptotic activity of BBR was evidenced by a decrease in TUNEL-positive cells and the percentage of apoptotic cells, as determined by flow cytometry, in conjunction with diminished levels of BCL2-associated X protein/B cell lymphoma 2 (BAX/BCL2) in heart tissues. Mechanistically, BBR was found to ameliorate diabetic cardiomyopathy by upregulating the expression of myocardial methionine sulfoxide reductase A (MsrA) and concurrently suppressing cardiac CaMKII oxidation. Conclusions: BBR alleviates diabetic cardiomyopathy by inhibiting myocardial apoptosis and oxidative stress through the MsrA and CaMKII signaling pathways.","PeriodicalId":41559,"journal":{"name":"Cardiovascular Innovations and Applications","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135444950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expert Consensus on ECG Identification Applied in the Insurance Industry✰ 心电识别在保险业应用的专家共识

4区医学

Cardiovascular Innovations and Applications Pub Date : 2023-01-01 DOI: 10.15212/cvia.2023.0061

Zhongjian Li, Kangyin Chen, Shifeng Li, Tong Liu

{"title":"Expert Consensus on ECG Identification Applied in the Insurance Industry✰","authors":"Zhongjian Li, Kangyin Chen, Shifeng Li, Tong Liu","doi":"10.15212/cvia.2023.0061","DOIUrl":"https://doi.org/10.15212/cvia.2023.0061","url":null,"abstract":"Electrocardiograms (ECGs) have the potential to be used as a reliable source of information for human identity recognition due to their universality, portability, and unique and stable biological identification features. This method enriches and refines existing biometric identification techniques, and is suitable for customer identity identification in the insurance industry. This article has the following objectives: 1) to introduce biometric identification techniques commonly used in the insurance industry, including ECG biometric identification techniques, and their advantages; 2) to discuss major aspects of ECG biometric identification techniques; 3) to systematically review the most recent advances in ECG identification and extraction characteristics from research in China and other countries; 4) to outline the technical aspects of using ECGs for recognizing client identity in the insurance industry; and 5) to discuss the future of ECGs in identity recognition. This article is aimed at further promoting the application of living personal ECG identification techniques in the insurance industry, and extending it to areas including medical insurance, banking, justice, public security, military, government, enterprises, and other departments and areas in which identification is needed to promote social stability and national security.","PeriodicalId":41559,"journal":{"name":"Cardiovascular Innovations and Applications","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135846121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intracoronary Electrocardiography-guided Strategy for the Treatment of Coronary Bifurcation Lesions 冠状动脉内心电图引导下治疗冠状动脉分叉病变的策略

4区医学

Cardiovascular Innovations and Applications Pub Date : 2023-01-01 DOI: 10.15212/cvia.2023.0055

Dobrin Vassilev, Niya Mileva, Panayot Panayotov, Krasimir Kostov, Kenan Yumerov, Nikolay Petkov, Carlos Collet, Gianluca Rigatelli, Robert J. Gil, Thach Nguyen

{"title":"Intracoronary Electrocardiography-guided Strategy for the Treatment of Coronary Bifurcation Lesions","authors":"Dobrin Vassilev, Niya Mileva, Panayot Panayotov, Krasimir Kostov, Kenan Yumerov, Nikolay Petkov, Carlos Collet, Gianluca Rigatelli, Robert J. Gil, Thach Nguyen","doi":"10.15212/cvia.2023.0055","DOIUrl":"https://doi.org/10.15212/cvia.2023.0055","url":null,"abstract":"Introduction: Revascularization of bifurcation lesions remains an interventional challenge. Intracoronary electrocardiograms can predict the functional significance of side branch stenosis after bifurcation stenting. Aim: This study was aimed at evaluating the effects of an intracoronary ECG electrocardiography (icECG)-guided revascularization strategy, compared with the currently accepted standard of care, on the clinical outcomes of patients after coronary bifurcation stenting. Methods: Patients with coronary bifurcation lesions who underwent percutaneous revascularization were enrolled in a prospective all-comers’ registry. Clinical outcomes were compared between patients who underwent icECG-guided revascularization versus the current standard of care (SOC), provisional stenting. Results: A total of 768 patients were included in the analysis: 349 were treated with an icECG-guided strategy, and 419 received SOC. The overall all-cause death rate was 23.2%, and the cardiovascular death rate was 15.9%. Patients with icECG guidance had significantly lower all-cause mortality (20.3% vs. 25.5% for icECG vs. SOC, log-rank P = 0.006) and cardiovascular mortality (12.6% vs. 18.6% for icECG vs. SOC, log-rank P = 0.004). The decrease in mortality was most pronounced in patients with no increase or a moderate increase in troponin post-PCI, or with higher-than-normal baseline troponin concentrations. Conclusion: An icECG-guided strategy for coronary bifurcation PCI led to lower patient mortality than the provisional stenting strategy.","PeriodicalId":41559,"journal":{"name":"Cardiovascular Innovations and Applications","volume":"126 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136259078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inappropriate Activation of TLR4/NF-κB is a Cause of Heart Failure TLR4/NF-κB的不适当激活是心力衰竭的原因之一

IF 0.5 4区医学

Cardiovascular Innovations and Applications Pub Date : 2022-12-15 DOI: 10.15212/cvia.2022.0020

Jiedong Zhou, Hui Lin, Tingting Lv, Jinjin Hao, Hanlin Zhang, Shimin Sun, Juntao Yang, J. Chi, Hangyuan Guo

{"title":"Inappropriate Activation of TLR4/NF-κB is a Cause of Heart Failure","authors":"Jiedong Zhou, Hui Lin, Tingting Lv, Jinjin Hao, Hanlin Zhang, Shimin Sun, Juntao Yang, J. Chi, Hangyuan Guo","doi":"10.15212/cvia.2022.0020","DOIUrl":"https://doi.org/10.15212/cvia.2022.0020","url":null,"abstract":"\u0000Significance: Heart failure, a disease with extremely high incidence, is closely associated with inflammation and oxidative stress. The Toll-like receptor 4 (TLR4)/nuclear factor kappa-B (NF-κB) pathway plays an important role in the occurrence and development of heart failure.\u0000\u0000Recent advances: Previous studies have shown that TLR4/NF-κB causes heart failure by inducing oxidative stress and inflammation; damaging the endothelia; promoting fibrosis; and inducing myocardial hypertrophy, apoptosis, pyroptosis, and autophagy.\u0000\u0000Critical issues: Understanding the pathogenesis of heart failure is essential for the treatment of this disease. In this review, we outline the mechanisms underlying TLR4/NF-κB pathway-mediated heart failure and discuss drugs that alleviate heart failure by regulating the TLR4/NF-κB pathway.\u0000\u0000Future directions: During TLR4/NF-κB overactivation, interventions targeting specific receptor antagonists may effectively alleviate heart failure, thus providing a basis for the development of new anti-heart failure drugs.","PeriodicalId":41559,"journal":{"name":"Cardiovascular Innovations and Applications","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42803145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to: Staged Revascularization for Chronic Total Occlusion in the Non-IRA in Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: An Updated Systematic Review and Meta-analysis st段抬高型心肌梗死接受初级经皮冠状动脉介入治疗的非ira慢性全闭塞患者的分期血运重建术:一项最新的系统评价和荟萃分析

IF 0.5 4区医学

Cardiovascular Innovations and Applications Pub Date : 2022-12-15 DOI: 10.15212/cvia.2022.0022

Yu Geng, Yintang Wang, Lianfeng Liu, Guobin Miao, Ou Zhang, Yajun Xue, Ping Zhang

{"title":"Corrigendum to: Staged Revascularization for Chronic Total Occlusion in the Non-IRA in Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: An Updated Systematic Review and Meta-analysis","authors":"Yu Geng, Yintang Wang, Lianfeng Liu, Guobin Miao, Ou Zhang, Yajun Xue, Ping Zhang","doi":"10.15212/cvia.2022.0022","DOIUrl":"https://doi.org/10.15212/cvia.2022.0022","url":null,"abstract":"Objectives: Meta-analysis was performed to evaluate the effect of staged revascularization with concomitant chronic total occlusion (CTO) in the non-infarct-associated artery (non-IRA) in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (p-PCI). Methods: Various electronic databases were searched for studies published from inception to June, 2021. The primary endpoint was all-cause death, and the secondary endpoint was a composite of major adverse cardiac events (MACEs). Odds ratios (ORs) were pooled with 95% confidence intervals (CIs) for dichotomous data. Results: Seven studies involving 1540 participants were included in the final analysis. Pooled analyses revealed that patients with successful staged revascularization for CTO in non-IRA with STEMI treated with p-PCI had overall lower all-cause death (OR, 0.46; 95% CI, 0.23–0.95), cardiac death (OR, 0.43; 95% CI, 0.20–0.91), MACEs (OR, 0.47; 95% CI, 0.32–0.69) and heart failure (OR, 0.57; 95% CI, 0.37–0.89) compared with the occluded CTO group. No significant differences were observed between groups regarding myocardial infarction and re-peated revascularization. Conclusions: Successful revascularization of CTO in the non-IRA was associated with better outcomes in patients with STEMI treated with p-PCI.","PeriodicalId":41559,"journal":{"name":"Cardiovascular Innovations and Applications","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48490238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The 33rd Great Wall International Congress of Cardiology Asian Heart Society Congress 2022 2022年第33届长城国际心脏病学大会亚洲心脏学会大会

IF 0.5 4区医学

Cardiovascular Innovations and Applications Pub Date : 2022-10-01 DOI: 10.15212/cvia.2022.0015

引用次数: 0

In Memoriam: C. Richard Conti, MD (1934 ‐ 2022), Founding Editor-in-Chief of Cardiovascular Innovations and Applications 纪念：C.Richard Conti，医学博士（1934‐2022），《心血管创新与应用》创始主编

IF 0.5 4区医学

Cardiovascular Innovations and Applications Pub Date : 2022-09-01 DOI: 10.15212/cvia.2022.0008

引用次数: 0

Common Statistical Methods and Reporting of Results in Medical Research 医学研究中常见的统计方法和结果报告

IF 0.5 4区医学

Cardiovascular Innovations and Applications Pub Date : 2022-05-01 DOI: 10.15212/cvia.2022.0001

G. Feng, Guoyou Qin, Tao Zhang, Zheng Chen, Yang Zhao

引用次数: 0

The Clinical Value of Syntax Scores in Predicting Coronary Artery Disease Outcomes 句法评分在预测冠状动脉疾病预后中的临床价值

IF 0.5 4区医学

Cardiovascular Innovations and Applications Pub Date : 2022-01-01 DOI: 10.15212/cvia.2022.0002

Lutfu Askin

引用次数: 3

Termination of Recurrent Atrial Fibrillation by Superior Vena Cava Isolation: A Case Report 上腔静脉隔离终止复发性心房颤动1例报告

IF 0.5 4区医学

Cardiovascular Innovations and Applications Pub Date : 2022-01-01 DOI: 10.15212/cvia.2022.0017

Dechun Yin

引用次数: 1